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Platinum-based drugs are popular in clinics as chemotherapeutic agents to treat solid tumors. However,
severe side effects such as nephro- and neurotoxicity impose strict dosage limitations that can lead to the
development of drug resistance and tumor relapse. To overcome these issues Pt(IV) prodrugs and plati-
num delivery systems might represent the next generation of platinum-based drugs. In this study four
novel Pt(II) complexes (namely, PEG-Glu-Pt-EDA, PEG-Glu-Pt-DACH, PEG-Mal-Pt-EDA and PEG-Mal-
Pt-DACH) were synthesized and a general strategy to covalently bind them to iron oxide nanoparticles
was developed. The intracellular uptake and cell distribution studies of Pt-tethered magnetic nano-
particles on breast and ovarian cancer cell line models indicate that binding of the Pt complexes to the
nanoparticles facilitates, for all the complexes, cellular internalization. Moreover, the magnetic nano-
particles (MNPs), as shown in a magnetofection experiment, enhance the uptake of MNP-Pt conjugates if
a magnet is placed beneath the culture dish of tumor cells. As shown by a Pt release experiment, intra-
nuclear platinum quantification and TEM analysis on cell sections, the presence of a pH-sensitive dicar-
boxylic group coordinating the Pt complex, triggers platinum dissociation from the NP surface. In
addition, the triazole moiety facilitates endosomal swelling and the leakage of platinum from the endo-
somes with intranuclear localization of platinum release by the NPs. Finally, as assessed by MTT, caspase,
calcein/ethidium bromide live/dead assays, among the four NP-Pt conjugates, the NP-Glu-Pt-EDA
complex having a glutamate ring and ethylenediamine as a chelating amine group of the platinum
showed higher cytotoxicity than the other three MNP–platinum conjugates.
Introduction
Pt-Based drugs cover almost 50% of chemotherapeutic
agents, and they are used to treat malignant solid tumors (i.e.
pancreatic, testicular, cervical, ovarian cancers, etc.).1,2 Despite
cisplatin, only other two platinum based molecules,
namely carboplatin and oxaliplatin, have been approved for
use on humans.3,4 These drugs are all square-planar
platinum(II) complexes with a Pt atom that is coordinated to
two leaving (the carboxylic groups) and two non-leaving amine
groups.5 The nature of these two types of chemical groups
affects the solubility, stability, efficacy and toxicity of the
drugs.6
Pt compounds however are hampered by dose-limiting toxic
side effects, including nephrotoxicity, neurotoxicity, drug resis-
tance and tumor relapse.7 The latter two effects generally arise
from poor accumulation levels of platinum in tumor tissues,
low cellular uptake,8 drug inactivation by intracellular gluta-
thione,9 and the DNA repairing mechanisms developed by
tumor cells.10,11 Nanocarriers could mitigate these side effects
at different levels: (i) they improve the solubility of the drug
while prolonging its circulation time; (ii) they penetrate deep
the tumor; (iii) they enable a triggered release of the Pt com-
plexes, which consequently reduce the drug resistance and
allow lower drug doses to be used.12,13
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Stimuli responsive nano- and mesoscale carriers in which a
chemotherapeutic agent can be simply encapsulated or co-
valently attached to the surface and be released under specific
stimuli have shown promising results.14–17 Some of these
systems have also been successfully tested in animal models,
showing a remarkable reduction of unwanted side effects and
decreased drug resistance.13,18–21 The composition of the
carrier together with the structure of the drug dictates the
loading capability and the release profile of the drug itself.22
In addition, its ability to tune size and surface chemistry of
nanoparticles also allows the control of their circulation time,
biodistribution, immune sequestration and clearance.23 The
optimization of these features over the last few years has led to
the first FDA approved nanoformulations for drug delivery in
chemotherapy (i.e. Doxil, Abraxane, and Onivyde).24 In the
case of platinum, a liposomal formulation of cisplatin, namely
Lipoplatin, is currently under clinical validation for the treat-
ment of ovarian and pancreatic cancer.25
In addition to lipid-based vesicles,26 other targeted nano-
particles with triggered release are under development, such
as those made of an inorganic core.14,22
For example, gold nanoparticles have been engineered
through linker molecules that anchor cisplatin27 or to bind
oxaliplatin,28,29 or with a specific oligonucleotide sequence to
link Pt(IV).30 In another study, cyclodextrin-capped gold par-
ticles were conjugated to an adamantine–platinum complex.31
Gold-based heterostructures such as gold-coated iron oxide
nanoparticles32 and dumbbell-like gold–magnetite nanocrys-
tals have also been exploited for platinum delivery onto cancer
cell lines.32–35 Despite the successful targeting delivery and
intracellular toxicity of these nanosystems, the clinical appli-
cation of gold-based nanoparticles is limited by their non-
degradable composition. An in vivo study on gold–iron oxide
heterostructures showed that after one year from the injection,
the iron oxide domain had been metabolized while the gold
one accumulated in several organs.36 More studies have con-
firmed the slow intracellular degradation and clearance of
differently coated magnetic iron oxide nanoparticles.15,33,37
The response of magnetic nanoparticles to magnetic stimu-
lation makes them eligible candidates not only as vectors for
anticancer drugs12 but also as contrast agents in Magnetic
Resonance Imaging (MRI)38 and heat agents for magnetic
hyperthermia.39–42
Platinum-based pharmaceuticals have been encapsulated
into host matrices at the surface of individual and/or clustered
MNPs.43–47 Different matrices such as gelatin,43 hyaluronic
acid,47 poly(ethyl-2-cyanoacrylate),48 and copolymers of poly
(methacrylic acid)-grafted-poly(ethyleneglycol methacrylate)
have been exploited,45 all with the purpose to protect the drug
molecules from inactivation. In two distinct studies, magnetic
micelles bearing a cisplatin prodrug were prepared by assem-
bling MNPs and phospholipids44 or MNPs and thermo-respon-
sive polymers.49 Sun’s group used porous hollow magnetite
nanoparticles as a hosting structure for cisplatin.43 More
recently, iron oxide nanoparticles co-loaded with both a Pt(IV)
prodrug were tested in tumor-bearing mice.50 It is worth
noting that in most of the aforementioned cases the drug was
not covalently attached to the surface of the magnetic nano-
particles. Directly linking the drug to the nanoparticles may
affect its internalization, biodistribution, and toxicity.
In this study, we have investigated the chemotherapeutic
potential of four novel Pt(II) complexes, synthesized by us, and
covalently conjugated to iron oxide nanoparticles. They are
formed by a cis-platinum complex containing two different
diamine groups and two different dicarboxylic moieties with a
long PEG side chain for binding to the nanoparticle. The plati-
num complexes are specifically designed to change their stabi-
lity at endosomal pH to release Pt(II) ions and at the same time
reincorporate protons into the endosomes. The internalization
and the resulting cytotoxic effect of the nanoconjugates were
proven in two cancer cell lines and compared to those of the
free drugs and commercially available cisplatin. The cellular
data show that the internalization of the Pt complexes conju-
gated to the nanoparticles is always enhanced compared to
that of free Pt complexes and it is even higher when the
uptake is performed in a magnetofection experiment with a
magnet placed beneath the cell dish. Among the four MNP-
platinum complexes developed, Pt-MNP nanoconjugates
having Pt linked through a glutamate ligand as the chelating
dicarboxylate and having EDA as an unexchangeable bidentate
ligand in their structure were the most effective anti-tumoral
compounds.
Results and discussion
Synthesis of Pt complexes
Four Pt complexes with different chelating dicarboxylates,
either malonate or glutamate, and diamino groups, either
ethylenediamine or a chiral diaminocyclohexane, were syn-
thesized (Fig. 1).
On the one hand, the malonate derivatives (PEG-Mal-Pt-
DACH and PEG-Mal-Pt-EDA) seemed particularly attractive
because their ring structure is similar to that of carboplatin,
although its spiro-cyclopropyl moiety was replaced with a
spacer to connect the drug to the nanoparticle. On the other
hand, the glutamic acid derivatives (PEG-Glu-Pt-DACH and
PEG-Glu-Pt-EDA) have an eight-membered ring chelating dicar-
boxylate that, in principle, should facilitate platinum release.
Similar to the malonate derivatives, a spacer was bound to the
α-amino group for anchoring the metal complex to the nano-
particle. In both cases, the copper catalysed 3 + 2 cycloaddition
reaction (click chemistry) between a terminal alkyne on the
dicarboxylate side chain and an azido modified poly(ethylene
glycol) (PEG) spacer provided a simple strategy for the incor-
poration of an amino moiety at the end of the chain
(Scheme 1). This group easily allowed the binding of the drug
derivatives to the nanoparticle surface through simple amide
bond formation. In addition to the two carboxylates, two
different bidentate amine ligands were selected for this study.
The first one, namely (1R,2R)-1,2-diaminocyclohexane (DACH),
is identical to the one used in the commercial oxaliplatin. The
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second one, ethylenediamine (EDA), was chosen due to its
structural simplicity and because it has already been shown to
give promising results with regard to its use in photoactive Pt
(IV) complexes.51,52
The synthesis of the platinum complexes is illustrated in
Scheme 1. The first step was the protection of the amino group
on a commercially available PEG derivative that was treated
with trityl chloride in the presence of diisopropylethylamine to
provide azide A with a yield of 83% (as determined by NMR,
see the ESI† for the NMR spectra of the compounds involved
in the synthesis). In parallel, N-Boc-Glu(Bn)-OMe was depro-
tected with trifluoroacetic acid (TFA) and then coupled to Boc-
protected propargylglycine to obtain dipeptide B with a yield
of 93%. The click reaction between the azido derivative A and
either dimethyl propargylmalonate or dipeptide B resulted in
the corresponding triazole derivatives with a yield of 71% and
72%, respectively. The platinum complexes were prepared by
reacting dinitroplatinum compounds, either Pt(NO3)2-DAE or
Pt(NO3)2-DACH, with the dicarboxylate salts of the triazole
derivatives previously obtained by the basic hydrolysis of
methyl esters. Finally, the trityl protecting groups were
removed after treatment with the acidic Dowex resin thus yield-
ing the four Pt-derivatives (PEG-Glu-Pt-DACH, PEG-Glu-Pt-EDA,
PEG-Mal-Pt-DACH, and PEG-Glu-Pt-EDA) ready for conjugation
to the magnetic nanoparticles (MNPs) through simple amide
bonds (Fig. 2).
Preparation and characterization of the nanoparticles
conjugated to the Pt-complexes
Magnetic iron oxide nanoparticles (with an average size of
10 nm) were prepared according to a thermal decomposition
method,53 and then transferred into water by means of a
polymer encapsulation procedure with polymaleic anhydride
octadecene.54 After solubilization, the amphiphilic polymer
exposes to the outer environment carboxylic groups, which
were used to link the platinum derivatives. Before attaching
the drug, it was necessary to pre-functionalize the surface of
the nanoparticles with some PEG molecules to ensure their
stability in DMSO, the solvent used during the coupling reac-
tion to dissolve the Pt complexes. The final nanoparticle–plati-
num complexes were transferred into PBS buffer and kept at
4 °C prior to use. It is worth mentioning that the choice of this
polymer coated and PEG functionalized MNPs was mainly dic-
tated by their safety and biocompatibility even at an injection
dose as high as 0.8–1.0 mg of iron, as previously demonstrated
by us in an in vivo biodistribution study on a murine model.55
The four MNP-Pt conjugates were characterized by means
of dynamic light scattering (DLS), gel electrophoresis, elemen-
tal analysis (Fig. 2), transmission electron microscopy (TEM)
(Fig. 1SI†), and Fourier Transform Infrared (FTIR) spectroscopy
(Fig. 3).
For their conjugation to the MNPs, the number of Pt mole-
cules to be added per nanoparticle needed to be optimized in
order to achieve the right balance between linking a
sufficiently toxic amount of Pt complexes to each nanoparticle
and to be able to preserve the stability and solubility of the
nanoparticles under physiological conditions.
Fig. 1 Top: The structure of commercially available cisplatin derivatives and photoactivated diodoplatinum(VI) complexes. Bottom: The platinum
complexes prepared in this work.
Scheme 1 Synthetic strategy used for the preparation of PEG-Glu-Pt-
DACH, PEG-Glu-Pt-EDA, PEG-Mal-Pt-DACH, and PEG-Glu-Pt-EDA
platinum complexes.
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The hydrodynamic diameters verified that the size of the
MNP-Pt conjugates shifted towards larger values than that of
the sample coated with only PEG molecules, but the overall
size was smaller than 100 nm (Fig. 2, panel d). The MNPs
bearing the PEG-Glu-Pt-DACH complex showed the largest dia-
meter, likely due to the tendency to form clusters and interpar-
ticle interactions, as also observed by gel electrophoresis
(Fig. 2, panel e). The surface charge was quite negative for all
the samples, with an average value close to −30 mV. The
average amount of Pt complexes linked to each nanoparticle
was estimated by means of elemental analysis, ranging from
about 70 to 100 metal complexes attached per nanoparticle
depending on the preparation conditions and on the type of Pt
complex (last column of the table of Fig. 2). The pattern of gel
migration clearly showed the different delays of the nano-
particle bands at each step of functionalization especially
when comparing the polymer coated NPs with the PEG coated
up to those conjugated to the Pt-complexes. As an example, in
the agarose gel electrophoresis shown in Fig. 2e, the MNP-Pt
loaded for the electrophoretic run carried an average amount
of 50 Pt molecules per nanoparticle. The gel electrophoresis
pattern of the four MNP-Pt conjugates showed that, under the
Fig. 2 (a) Representative drawing of the MNP-PEG-Glu-Pt-DACH conjugate. TEM images of the nanoparticles after water solubilization (b) and (c)
surface functionalization with PEG-Glu-Pt-EDA. (d) The table reports the average hydrodynamic size and surface charge values for the nanoparticles
conjugated to the different platinum complexes, as determined by DLS, as well as the average number of platinum complexes linked per type of
nanoparticle, as assessed by elemental analysis using the Pt/Fe ratio. (e) Agarose gel electrophoresis characterization showing the mobility of the
nanoparticles after each step of surface functionalization.
Fig. 3 FTIR spectra of (a) the synthesized Pt complexes and (b) the MNP before and after conjugation to PEG-Glu-Pt-EDA. In panel (b) the spectrum
of PEG-Glu-Pt-EDA is also reported for comparison.
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same conjugation conditions, the bands corresponding to the
complexes that contain glutamate are more delayed than those
containing malonate. It should be noted that the MNP-Glu-Pt-
DACH sample was partially stuck in the well, highlighting the
tendency of the conjugate to aggregate.
Additionally, representative TEM images of the nano-
particles at each step of preparation, showing well dispersed
nanoparticles, with the exception of the MNP-PEG-Glu-Pt-
DACH sample that evidenced a tendency to aggregate, con-
firmed the reduced stability of this nanoconjugate compared
to the others (Fig. 1b and c and Fig. 1SI†).
The FTIR spectra of the Pt complexes and those of the MNP
at different steps of the preparation were recorded to verify the
change in surface functionalization (Fig. 3). On the one hand,
for the four Pt complexes (Fig. 3a) the peaks of the C–O
stretching, C–H and O–H bending in the region from about
950 to 1700 cm−1 can be recognized, together with the C–H
stretching in the region from 2850 and 3000 cm−1 were
observed. On the other hand, the spectrum of the MNP-PEG
showed the typical signals of the free carboxylic acids exposed
on the outer surface, i.e. the asymmetric carbonyl stretching of
the carboxylate group (1645 cm−1, quite lower than typical
wavenumbers probably because of being involved in hydrogen
bonding) and the corresponding hydroxyl stretching (broad
peak at about 3400 cm−1) (Fig. 3b, brown curve). Despite some
PEG molecules being linked to the MNP, only very small bumps
could be observed for their typical C–O and C–H symmetric and
asymmetric stretching (1073, 2922 and 2850 cm−1, respectively).
Successful binding of the MNP to PEG-Glu-Pt-EDA was con-
firmed by the spectrum of the resulting MNP-Pt conjugates
(Fig. 3b, dark green curve) which clearly presented the peaks
belonging to both Pt complexes and PEG molecules. The FTIR
spectra of the other nanoconjugates presented similar profiles,
also indicating successful reactions (data not shown).
To study the pH-dependent release of the conjugated plati-
num, the MNP-Pt nanoconjugates were kept at 37 °C for either
24 or 48 h in solutions at a well-defined pH in the range of 3 to
7. The amount of Pt that separated from the nanoparticles was
recovered by filtration and quantified by elemental analysis,
and the data obtained were plotted as a percentage of the
initial platinum amount (Fig. 4). Having proven the presence
of platinum on the NPs, we further studied the Pt release for
all the Pt-conjugates by keeping the MNP-Pt conjugates in
solution while gradually reducing the pH towards acidic values
and evaluating the free platinum after separation from the NP
fraction. At a pH of 3, almost 40% of Pt was released into the
solution after 24 h, and this value increased up to 80% and
85% after 48 h in the case of MNP-Glu-Pt-EDA and MNP-Mal-
Pt-EDA, respectively. At a pH of 4.0–4.5, which corresponds to
the lysosomal pH, approximately 20% of Pt was detected after
24 h, whereas the average free platinum for all the nanoconju-
gates ranged between 50 and 70% after 48 h. On the other
hand, at the physiological pH 7 the amount of Pt released was
as low as about 10% and 20% after 24 h and 48 h, respectively,
suggesting a potential good stability of the drugs before cellu-
lar internalization.
It is widely known that in an endocytic pathway, the pH
drops from 6.5 in early endosomes to 4 in mature lysosomes
and might facilitate the dissociation of platinum from the
nanoparticle surface.56,57
Cellular studies
Based on these Pt loading and release findings, cellular
studies were performed to assess the cytotoxic activity of the
free Pt complexes and of the MNP-Pt conjugates in two tumour
cell lines that display different sensitivities to platinum-based
chemotherapy. In detail, ovarian cancer cells (IGROV-1) and
breast cancer cells (MDA-MB-231) were chosen as in vitro
models, the latter being generally recognized as cells quite
resistant to platinum-based drug treatments.58–60
Viability and apoptotic cellular assays (namely MTT and
caspase) were performed to investigate the efficacy of both free
and nanoparticle-bound platinum complexes on both cell
lines.
First, a MTT proliferation assay was carried out to deter-
mine the inhibitory concentration (IC50) values of Pt com-
plexes (either free or conjugated to the MNP) after 24 h of incu-
bation with IGROV-1 and MDA-MB-231 cells. Cisplatin was
also tested as an additional reference for being routinely used
in the clinical treatment of several cancers. Remarkably, all the
free Pt complexes showed greater toxicity (IC50 between 6 and
8 µM) as compared to cisplatin (IC50 around 98 µM and 80 µM
for the MDA-MB-231 and IGRO-1 cells, respectively). This
means that the bare Pt complexes are on average 10 times
more toxic than standard cisplatin. In addition, the IC50 values
further decreased when the Pt drugs were bound to the nano-
particles (Table 1). As expected, the IGROV-1 cells were more
sensitive to the toxic activity of the Pt derivatives than the
MDA-MB-231 ones. Indeed, in the case of IGROV-1 that had
been administered with MNP-Glu-Pt-EDA and MNP-Glu-Pt-
DACH, the IC50 dropped down to 1.6 and 1.2 µM, respectively,
Fig. 4 Release profile of Pt from MNP-Pt conjugates after 24 h and
48 h at various pH values. The lines are traced only for guiding the eyes;
they do not represent any mathematical fit. For each data point, an
average of at least 3 measurements has been recorded.
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while MDA-MB-231 cells that had been incubated with the
same nanoparticles showed an IC50 equal to 5.3 and 5.2 µM,
respectively. This corresponds to a further 3–4 fold decrease of
IC50 as compared to the corresponding free drug. The same
trend was also detected when the two cell lines were incubated
with MNP-Mal-Pt-EDA and MNP-Mal-Pt-DACH, but the differ-
ence in the IC50 was less significant (the values for the
IGROV-1 were 4.2 and 4 µM, and the values for the
MDA-MB-231 cells were 6.2 and 5.8 µM, respectively).
These results suggest that the Pt complexes and MNPs-Pt
conjugates affect cell survival significantly as compared to cis-
platin and there are correlations between the structures of the
nanoconjugates, platinum complexes and cell line types.
Indeed, as a first observation, the Pt-based drugs seem to
induce a more cytotoxic effect when bound to the nano-
particles, with respect to that of the free Pt complexes at the
same dose of administration. These results are in line with the
literature, as it has already been reported that the use of drug
carriers could facilitate drug uptake and accumulation by over-
coming several limitations of traditional drugs.3,61
The cell response also depends on the genetic and epige-
netic characteristics of the cell lineage and on the acquisition
of drug resistance upon exposure.62 Several drug resistance
mechanisms have already been reported, from the over-
expression of efflux pump Pgp to the activation of DNA repair
mechanisms.63 Thus, it might be assumed that under the
same experimental conditions, the MDA-MB-231 cells exhibi-
ted some resistance to the Pt-based drugs (or at least a reduced
sensitivity to drug action), since this behaviour has been par-
tially identified over the last few years.64
In an attempt to define the interactions between
MDA-MB-231 or IGROV-1 cells and Pt compounds, a caspase-3
apoptotic assay was performed. The two cell lines were incu-
bated with either the free Pt complexes or the MNP derivatives
at a Pt concentration equal to 2 µM – a value that is close to
the IC50 of the most effective nanoconjugates.
As reported in Fig. 5, the activation of caspase 3, which is a
common killing factor in the apoptotic process, was detected
by using a fluorogenic substrate which is cleaved upon stimu-
lation. It is evident that, while MNP-PEG induced an activation
close to 20% in both cell lines, the free Pt compounds and
their nanoconjugates triggered a significant activation of
caspase 3. This process seemed to be more prominent in
IGROV-1 cells than in MDA-MB-231 ones, and it was boosted
in cells that had been administered with MNP bearing the Pt
complexes with respect to those that had been incubated with
free Pt molecules. These data were in accordance with those
obtained by the MTT assay, and they confirmed that IGROV-1
cells are more sensitive than MDA-MB-231 cells to the Pt
drugs.
Table 1 IC50 (µM) values estimated for either free or MNP-bound Pt
conjugates after 24 h of incubation with MDA-MB231 and IGROV-1 cells.
Cisplatin was also evaluated as an additional reference. The assays were
normalized with respect to the total amount of Pt. The data represent
the average and the standard deviation of three independent measure-
ments. Statistical analysis was performed via the t-test: p < 0.01 when
comparing the data of free Pt complexes with IC50 values of MNP-Pt in
both cell lines; p < 0.01 when comparing the IC50 values of MNP-Pt of
MDA-MB231 with those of IGROV-1 cells
MDA-MB-231 IGROV-1
Tested sample IC50 (µM) IC50 (µM)
PEG-Glu-Pt-EDA 7.1 ± 0.2 5.8 ± 0.3
PEG-Glu-Pt-DACH 8.3 ± 0.1 7.9 ± 0.1
PEG-Mal-Pt-EDA 6.2 ± 0.1 6.8 ± 0.1
PEG-Mal-Pt-DACH 7.4 ± 0.1 7.5 ± 0.1
MNP-PEG-Glu-Pt-EDA 5.3 ± 0.2 1.6 ± 0.4
MNP-PEG-Glu-Pt-DACH 5.2 ± 0.4 1.2 ± 0.4
MNP-PEG-Mal-Pt-EDA 6.2 ± 0.1 4.2 ± 0.1
MNP-PEG-Mal-Pt-DACH 5.8 ± 0.1 4.0 ± 0.4
Cisplatin 97.6 ± 5.1 79.8 ± 0.3
Fig. 5 Caspase-3 assay performed with IGROV-1 and MDA-MB-231 cells incubated for 24 h with the free Pt complexes, the four MNP-Pt conju-
gates, and MNP-PEG. The results are reported as a percentage of the fluorescence intensity of each sample with respect to the untreated control
cells. The values and the SD were obtained from 3 independent experiments. The t-test carried out on the two cellular data sets revealed a signifi-
cant difference (p < 0.01) among the cells incubated with the free Pt complexes and those administered with the Pt-MNP conjugates.
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Activation of the apoptotic process seemed to be relatively
constant over time, which is likely due to the progressive
uptake of either the Pt compounds or the MNPs, subsequently
prolonging their effects on cell homeostasis.
Furthermore, unlike in the case of the MTT assay, there
were no considerable differences within each group of samples
for each cell line. Indeed, the fluorescence intensity detected in
the cells after incubation with the Pt complexes at both time
points was rather similar (the values ranged from 42% to 51% in
the case of IGROV-1, and from 26% to 36% in the case of
MDA-MB-231). Similar results were found for the four MNP-Pt
conjugates (the values ranged from 67% to 74% in the case of
IGROV-1, and from 54% to 64% in the case of MDA-MB-231).
It might be expected that the activation of the caspase
cascade would be more consistent in the case of Pt-tethered
nanoparticles as compared to free Pt complexes, but it should
be noted that, as described in the next sections, the uptake
mechanism and the intracellular trafficking of the Pt conju-
gates are different from those of the free complexes, thus likely
leading to cytotoxic effects that involve multiple molecular
events.
Since the best overall results from the characterization per-
formed so far were obtained with the PEG-Glu-Pt-EDA drug
and the corresponding nanoconjugate, we decided to focus
our attention on those compounds.
A live/dead assay was also performed on MDA-MB-231 cells,
which were incubated with either PEG-Glu-Pt-EDA or MNP-Glu-
Pt-EDA for 24 h. The cells treated with MNP-PEG-Glu-Pt-EDA
exhibited a very poor fluorescence in the green channel and a
strong fluorescence in the ethidium bromide channel, thus
indicating a loss of membrane integrity and cellular damage
with consequent necrosis (Fig. 2SI†). In the case of the cells
that were incubated with the free platinum complex, PEG-Glu-
Pt-EDA, the merged channel provided an image with orange
cells due to the overlap between the calcein and ethidium
bromide channel signals. Thus, it is likely that these cells did
not suffer as much as those that were incubated with
MNP-PEG-Glu-Pt-EDA. In contrast, control cells showed green
fluorescence in the calcein channel, which is a sign of vital
status.
Quantitative analyses of the fluorescent pixels in both chan-
nels (Fig. 3SI†) confirmed that the signal associated with ethi-
dium bromide tremendously increased in the Pt-treated cells,
while the signal associated with calcein diminished.
The results obtained by the two viability assays and the live/
dead assay (the latter in the case of MDA-MB-231 cells only)
suggest that, upon exposure to Pt compounds, the amplitude
of the cellular damage and the activation of multiple subcellu-
lar processes could lead to the activation of either apoptosis or
necrosis, depending on the cell status and the ability to repair
DNA damage. However, regardless of the type of Pt complex
tested, it seems that the toxic effect of the drug is more pro-
nounced when it is conjugated to the nanoparticle, which is
likely due to an enhanced and faster internalization.
Effect of a magnet on the cellular uptake
The magnetic response of iron oxide nanoparticles is a valu-
able tool to drag any cargo associated with the magnetic nano-
particles.65 Here, in a magnetofection experiment a NdFeB
magnet was placed under the cell culture well while the cells
were challenged with either PEG-Glu-Pt-EDA or MNP-PEG-Glu-
Pt-EDA. The effect of magnetic delivery on cell viability is
shown in Fig. 6.
Cells were incubated with a concentration of Pt (either as a
Pt complex or a MNP-Pt conjugate) equal to 750 nM (an
amount below the IC50), corresponding to 5.5 nM iron oxide
nanoparticles for MNP-PEG-Glu-Pt-EDA. Application of the
magnet for 24 h under the cell culture plate boosted the Pt
delivery with an evident increase of the cellular cytotoxicity
associated with the enhanced platinum delivery. Indeed, when
the magnet was applied, the viability of the cells incubated
with MNP-PEG-Glu-Pt-EDA dropped from 70 and 62% in the
case of IGROV-1 and MDA-MB-231 (in the absence of the
magnet) to 44 and 45% (in the presence of a magnet). As
expected, no differences were observed with or without the
magnetic field when the cells were incubated with the free Pt
complex.
Nanoparticle internalization and localization
To elucidate the contribution of the nanoparticle-mediated
delivery in combination with the magnetic guidance, a quanti-
tative estimation of Pt internalized by the cells was performed
by elemental analysis (Fig. 7). Both IGROV-1 and MDA-MB-231
cells were treated for 24 h with either PEG-Glu-Pt-EDA or
MNP-PEG-Glu-Pt-EDA with or without the application of a
magnetic field. Then the cells were processed to detect Pt
internalization for the Pt-MNP conjugates, the free Pt com-
plexes and the free cisplatin. After 24 h, the highest intracellu-
Fig. 6 Effect of the application of a magnetic field (MF) on the viability of IGROV-1 and MDA-MB-231 cells incubated for 24 h with either PEG-Glu-Pt-EDA
orMNP-PEG-Glu-Pt-EDA (* indicates p < 0.05 when compared with MNP-PEG-Glu-Pt-EDA. Statistical analysis was performed using the t-test).
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lar content of Pt was detected when the Pt complex was linked
to the nanoparticle (reaching 1.2 × 10−11 g per cell in IGROV-1
and 2.0 × 10−11 g per cell in MDA-MB-231, respectively) and it
was more than double when a magnetic field was applied
under the well (2.9 × 10−11 g per cell in IGROV-1 and 5.0 ×
10−11 g per cell in MDA-MB-231, respectively). However, the
intracellular amount of Pt was around one order of magnitude
smaller when the cells were administered with the free
PEG-Glu-Pt-EDA complex (1.8 × 10−12 g per cell in IGROV-1
and 2.9 × 10−12 g per cell in MDA-MB-231, respectively).
Remarkably, in the case of cisplatin the intracellular uptake
was even less, since the Pt amount detected was 1.5 × 10−13 g
per cell in IGROV-1 and 2.1 × 10−13 g per cell in MDA-MB-231,
respectively.
These results may be explained on the basis of the poor
solubility of the free cisplatin under physiological conditions,
which would explain the low cytotoxicity measured by the MTT
assay.
In contrast, the magnetic nanoparticles accelerated the Pt
internalization, facilitating its uptake even without applying a
magnetic field, probably through endocytosis, as already
reported in the literature.12 According to this process, the
nanoparticles, once engulfed within vesicular structures, are
usually confined to the perinuclear region where they remain
localized unless a physicochemical process (mediated by the
chemical composition or stimuli responsiveness of the nano-
particles, such the triazole moiety of the platinum complexes)
is activated. The triazole moieties by reincorporating protons
and counter ions from the cytoplasm into the endosomes may
cause rupture or destabilization of the endolysosome mem-
branes, and consequently the release of their content inside
the cytosol.66
With the aim of following the intracellular pathway of the
MNP-Pt complex, structural analysis of the cells incubated
with either MNP-PEG-Glu-Pt-EDA or MNP-PEG at sub-lethal
doses (Pt concentration equal to 0.25 µM) was performed by
electron microscopy (Fig. 8). After 1 h of incubation, the nano-
particles were clearly present in the endosomal vesicles, and
the morphology of the endosomes containing either MNP-PEG
(Fig. 8a) or MNP-PEG-Glu-Pt-EDA (Fig. 8b) was similar.
In another experiment, after the cells were incubated for
1 h with MNP-PEG-Glu-Pt-EDA or MNP-PEG, the cell medium
was replaced with a fresh one that did not contain nano-
particles or the Pt complex, and the cultures were kept for an
additional 24 h at 37 °C. The TEM images of the intracellular
uptake pathway showed that the endosome structure was dra-
matically altered, they appeared swollen and exhibited the
nanoparticles in a corona-like distribution (Fig. 8e and f).
Indeed, it seems that the MNP-PEG-Glu-Pt-EDA conjugate pro-
moted an osmotic imbalance, accompanied by water diffusion
and a consequent swelling of the endosomes. This effect was
not detected in the case of MNP-PEG that was incubated under
the same conditions (Fig. 8c and d; additional TEM images in
Fig. 4 and 5 of the ESI†). By analyzing and comparing the size
distribution of the endosomal vesicles (Fig. 6SI†), it became
apparent that they have a broad distribution in the cells incu-
bated with the MNP-Pt conjugate, ranging from 100 to 800 nm,
with two intense peaks at 250 and 500 nm, the latter popu-
lation being the most abundant. In the case of MNP-PEG, the
analysis showed a much more uniform distribution, between
200 and 400 nm, with a median endosomal size of 400 nm.
As suggested by our data, this peculiar behaviour can be
attributed to the structure of the Pt complexes. Indeed, the
presence of a triazole group has been often used as a pH-sensi-
tive group to trigger endosomal protonation and drug escape
in others types of cargo systems (i.e. cation lipids and modified
antibody structures).67,68
The triazole group in the Pt complex may facilitate the
entrance of protons, anions and water, favouring the high
osmotic pressure inside the endosome. The consequent swell-
ing of the endosomal vesicles and the acidic hydrolysis of the
platinum(II) complex enable the metal release and therefore
the endosomal escape, as shown in Fig. 8SI.† 69
Interestingly, the TEM images suggest that the swelling
process did not lead to the rupture of the endosomal vesicles
but only to the increase of their volume, which likely allowed
Fig. 7 Pt determination via elemental analysis on IGROV-1 cells (left panel) and MDA-MB-231 cells (right panel) incubated with either
MNP-PEG-Glu-Pt-EDA (a) without and (b) with the application of a magnetic field (MF), or (c) the free PEG-Glu-Pt-EDA complex or (d) cisplatin for
24 h.
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for the Pt escape, while the bulkier MNPs remained confined
to the endosomes (at least at sub-lethal doses), as already
reported by some of us.70
After 96 h, the enlarged vesicles were still visible in the
cytosol, although they looked less swelled, likely as the conse-
quence of the cellular attempt to restore the physiological
endosomal sizes (Fig. 7SI†).
To verify if the platinum complex reaches the nucleus and
binds itself to the deoxyguanosine residues, subsequently hin-
dering the DNA replication process, as already reported,71 we
have quantitatively determined the amount of intra-nuclear
platinum. To this aim, the DNA of the cells incubated with
either MNP-PEG-Glu-Pt-EDA or PEG-Glu-Pt-EDA (under the
same conditions used for the estimation of the intracellular
Fig. 8 TEM images of IGROV-1 cells incubated for 1 h with (a) MNP-PEG and (b) MNP-PEG-Glu-Pt-EDA. TEM images of IGROV-1 cells incubated
for 24 h with (c and d) MNP-PEG and (e and f) MNP-PEG-Glu-Pt-EDA. The red arrows indicate the endolysosomes containing the nanoparticles. The
green arrows indicate the swelling of the vesicular structures, observed only for MNP-PEG-Glu-Pt-EDA, in which the nanoparticles appear to be
arranged in circular geometries. The blue arrows point to the nuclear membrane. (d) and (f ) are the zoomed areas of (c) and (e), respectively.
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Pt) was extracted prior to the detection of Pt via elemental ana-
lysis. The results show that the absolute amount of intranuc-
lear Pt is higher when the cells were incubated with the MNP
bearing the Pt complex (1.5 and 0.78 pg in the case of IGROV-1
and MDA-MB-231, respectively) than with the free complex
(0.21 and 0.16 pg in the case of IGROV-1 and MDA-MB-231,
respectively) (Table 2).
Conclusions
In this study, four novel platinum complexes with amino ter-
minated PEG chain linkers were synthesized and then attached
to the surface of iron oxide nanoparticles. The platinum-based
drugs were specifically designed to have a chelating dicar-
boxylic acid moiety, as in the case of oxaliplatin, either malo-
nate or glutamate, and a diamino group, either EDA or DACH.
The amino-PEG on the side chain of the platinum complex
allowed its binding to iron oxide nanoparticles. The cyto-
toxicity assays showed that the MNP-Pt complexes were gener-
ally more cytotoxic than the corresponding free Pt-compounds
and cisplatin used as a gold standard. This was directly related
to the enhanced drug uptake when it is linked to the MNP
rather than the free complex. In the case of the MNP-deriva-
tives, internalization was further accelerated when an external
magnetic field was applied.
Finally, a possible explanation of the mechanism through
which the Pt complex detaches from nanoparticles and
escapes from the endosomal compartment has been provided.
As a first step, the pH-hydrolysis of the platinum–ligand
complex on the platinum–MNP conjugates, also verified in a
test tube, enables the uncoupling of the Pt ions from the nano-
particle surface, while the presence of a triazole moiety in the
platinum complex promotes the swelling of the cellular endo-
somes, the latter observed under TEM analysis, allowing the
endosomal escape of the platinum.
Indeed, the endocytic pathway often limits the intracellular
transport of drugs/nanoparticles since most of the carriers and
cargos become trapped within the nano-meso scale, generally
entering the cell via an endocytosis mechanism and remaining
confined within the vesicles without reaching their biological
target.72
Finally, the platinum intranuclear localization, as measured
by platinum associated with the DNA, enables the execution of
the anti-proliferation action. The highest cytotoxic effect was
observed for the Pt-nanoconjugates containing the glutamate
ligand as the chelating dicarboxylate and EDA as the diamino
group, yielding a nanodrug that proved to be more than order
of magnitude more efficient than standard cisplatin. This
nanoconjugate also reached lower IC50 concentrations when
compared to previous literature studies on Pt-based drugs
bound to iron oxide nanoparticles, such as porous hollow
Fe3O4 nanoparticles
43 and dumbbell-like Au–Fe3O4 nano-
particles73 for cisplatin delivery, or other magnetic nano-
particles designed to deliver different platinum(IV)
prodrugs,46,50 thus being a promising candidate for future
in vivo studies. As a next step, efforts should be made to
develop a single magnetic Pt-nanoconjugate that can merge
the physical magnetic accumulation and cytotoxicity effects of
the platinum compound with biomolecular targeting that can
recognize receptors overexpressing on the specific tumor
under treatment (such as AFRA antibody fragments that can
link folate receptors overexpressing on ovarian cancer cells55).
This would make the anti-tumoral treatment very specific
sparing healthy cells that do not express the receptors, and at
the same time, it would require fewer doses of anti-tumoral




fluorophosphate 3-oxide (N-HBTU), N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDC), alpha-amino acids,
amines, etc. were purchased from Novabiochem, Applied
Biosystems, Global Sales Manager, GL Biochem (Shanghai)
Ltd, China, Sigma-Aldrich or Across. The azido-PEG-amine
[N3–CH2–CH2–(O–CH2–CH2)10–O–CH2–CH2–NH2] was pur-
chased from Polypure AS (Oslo, Norway), and the Pt com-
pounds [PtCl2-EDA and K2PtCl4] were purchased from Alfa
Aesar. QuadraSil® AP was purchased from Aldrich. All reagents
and solvents were used as received unless otherwise stated.
Solvent mixtures for chromatography are reported as v/v ratios.
Column chromatography was performed on EM Science silica
gel 60 (230–400 mesh). CH2Cl2 and DIEA were distilled from
CaH2 over argon immediately prior to use.
General techniques
1H NMR spectra were recorded on a Bruker AMX 500 MHz
spectrometer or a Varian Mercury 300 MHz spectrometer.
Chemical shifts (δ) were reported in parts per million (ppm, δ)
relative to tetramethylsilane (δ = 0.00 ppm) or by the deuter-
ium solvent. 1H NMR splitting patterns are designated as
singlet (s), doublet (d), triplet (t), or quartet (q). Splitting pat-
terns that could not be easily interpreted are designated as
multiplet (m) or broad (br). 13C NMR spectra were recorded on
a Bruker AMX 500 MHz spectrometer or a Varian Mercury
300 MHz spectrometer. Carbon resonances were assigned by
using DEPT spectra obtained with phase angles of 135°.
Electrospray ionization (ESI) mass spectra were recorded on a
Bruker BIOTOF II mass spectrometer.
Table 2 Nuclear Pt determination via elemental analysis on IGROV-1
cells and MDA-MB-231 cells incubated with either MNP-PEG-Glu-Pt-
EDA or the free PEG-Glu-Pt-EDA complex for 24 h
Sample name: Pt (g per nucleus)
IGROV-1 MNP-PEG-Glu-Pt-EDA 1.5 × 10−12 ± 1.2 × 10−12
PEG-Glu-Pt-EDA 2.1 × 10−13 ± 2.6 × 10−14
MDA-MB-231 MNP-PEG-Glu-Pt-EDA 7.8 × 10−13 ± 1.7 × 10−14
PEG-Glu-Pt-EDA 1.6 × 10−13 ± 7.6 × 10−15
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Synthesis of Pt complexes
Azido-PEG-amine-Trt (A). A solution of Azido-PEG-amine
[N3–CH2–CH2–(O–CH2–CH2)11–NH2] (55 mg, 0.10 mmol) in
CH2Cl2 (1 mL) was treated with trityl chloride (56 mg,
0.19 mmol) and DIEA (33.4 µL, 0.19 mmol). The mixture was
stirred at room temperature for 12 h, and then an aqueous
solution of NH4Cl (sat. sol., 1 mL) was added. The solution
was poured into a separation funnel and extracted with CH2Cl2
(3 × 1 mL). The combined organic layers were dried with anhy-
drous Na2SO4 and then they were filtered and concentrated
under reduced pressure. The resulting residue was purified by
flash chromatography (1–2% MeOH in CH2Cl2) to give 65 mg
of A as a light-yellow oil [83%, Rf = 0.40 (5% MeOH/CH2Cl2)].
1H NMR (CDCl3, 300 MHz, δ): 7.55–7.43 (m, 6H), 7.30–7.16 (m,
9H), 3.76–3.50 (m, 42H), 3.39 (t, J = 5.1 Hz, 2H), 2.36 (t, J = 5.3
Hz, 2H), 2.08 (br, 2H). 13C NMR (CDCl3, 75 MHz, δ): 146.1 (C),
128.7 (CH), 127.7 (CH), 126.2 (CH), 77.6 (C), 71.3 (CH2), 70.7
(CH2), 70.6 (CH2), 70.1 (CH2), 70.0 (CH2), 50.7 (CH2), 43.1
(CH2) ppm. MS (ESI-TOF
+) [m/z (%)]: 851.4 ([MK]+, 12), 835.4
([MNa]+, 87), 813.5 ([MH]+, 4), 593.3 ([MNa − Trt]+, 48), 571.3
([MH − Trt]+, 100). HRMS (ESI) calculated for C43H64N4NaO11:
835.4464, found: 835.4474.
Boc-L-Pra-L-Glu(OBn)-OMe (B).
A solution of Boc-L-Glu(OBn)-OMe (108 mg, 0.31 mmol) in a
mixture of TFA/CH2Cl2 (1 : 1, 4 mL) was stirred at room temp-
erature. After 15 min, the solvent was removed under reduced
pressure and the resulting solid was dried under high vacuum
for 3 h. The resulting TFA salt was dissolved in CH2Cl2 (3 mL),
and then Boc-L-Pra-OH (66 mg, 0.31 mmol), N-HBTU (129 mg,
0.34 mmol) and DIEA (0.22 µL, 1.20 mmol) were successively
added. The mixture was stirred at room temperature for 2 h
and the solution was poured into a separation funnel and
washed with an aqueous solution of HCl (10%, 3 × 3 mL) and
NaHCO3 (sat. sol., 3 × 3 mL). The organic layer was dried with
anhydrous Na2SO4, and then it was filtered and concentrated
under reduced pressure. The resulting yellow oil was purified
by flash chromatography (50% EtOAc in hexanes) to give
129 mg of the dipeptide B as a white foam [93%, Rf = 0.55
(50% EtOAc in hexanes)]. 1H NMR (CDCl3, 500 MHz, δ): 7.29
(m, 5H), 7.12 (d, J = 7.8 Hz, 1H), 5.42 (d, J = 8.0 Hz, 1H), 5.06
(s, 2H), 4.61 (td, J = 7.9 and 5.1 Hz, 1H), 4.29 (br, 1H), 3.67 (s,
3H), 2.72 (ddd, J = 17.0, 5.8 and 2.7 Hz, 1H), 2.57 (ddd, J =
17.0, 5.8 and 2.3 Hz, 1H), 2.51–1.91 (m, 4H), 2.01 (t, J = 2.7 Hz,
1H), 1.43 (s, 9H) ppm. 13C NMR (CDCl3, 75 MHz, δ): 172.4
(CO), 171.8 (CO), 170.2 (CO), 155.3 (CO), 135.7 (C), 128.5 (CH),
128.4 (CH), 128.2 (CH), 80.4 (C), 79.3 (C), 71.7 (CH), 66.4
(CH2), 52.9 (CH), 52.5 (CH), 51.6 (CH3), 30.1 (CH2), 28.2 (CH3),
27.3 (CH2), 22.3 (CH2) ppm. MS (ESI-TOF
+) [m/z (%)]: 469.2
([MNa]+, 100), 413.1 ([MNa − tBu]+, 7), 369.1 ([MNa − Boc]+, 8).




A solution of Boc-L-Pra-L-Glu(OBn)-OMe (116 mg, 0.26 mmol)
in a mixture of H2O/MeOH (1 : 1, 40 mL) was treated with
CuSO4 (104 mg, 0.65 mmol) and sodium L-ascorbate (620 mg,
3.1 mmol). The mixture was stirred at room temperature for
15 min, and then a solution of azido-PEG-amine-Trt (A)
(211 mg, 0.26 mmol) in a mixture of H2O/MeOH (1 : 1, 5 mL)
was added. The mixture was stirred at room temperature for
24 h, and then the solution was treated with QuadraSil® AP
resin to remove any excess Cu. After stirring for 20 min, the
resin was filtered and washed with MeOH, and then the
solvent was removed under reduced pressure. The resulting
residue was purified by flash chromatography (1–3% MeOH in
CH2Cl2) to give 236 mg of Tr-PEG-Glu-OMe as a colorless oil
[72%, Rf = 0.60 (10% MeOH/CH2Cl2)].
1H NMR (CDCl3,
300 MHz, δ): 7.54 (s, 1H), 7.49–7.46 (m, 6H), 7.35 (m, 4H),
7.29–7.14 (m, 12H), 6.09 (br, 1H), 5.10 (s, 2H), 4.59–4.48 (br,
2H), 4.38 (q, J = 5.1 Hz, 2H), 3.77 (t, J = 5.2 Hz, 2H), 3.69 (s,
3H), 3.64–3.51 (m, 42H), 3.30 (dd, J = 14.9 and 5.2 Hz, 1H),
3.07 (dd, J = 15.0 and 5.4 Hz, 1H), 2.35 (t, J = 5.4 Hz, 2H),
2.24–2.08 (m, 4H), 1.45 (s, 9H) ppm. 13C NMR (CDCl3, 75 MHz,
δ): 172.3 (CO), 171.7 (CO), 171.2 (CO), 146.2 (CO), 143.3 (C),
135.8 (C), 128.7 (CH), 128.6 (CH), 128.4 (CH), 128.3 (CH), 127.8
(CH), 126.2 (CH), 123.6 (CH), 80.3 (C), 77.6 (C), 71.3 (CH2),
70.7 (CH2), 70.6 (CH2), 70.5 (CH2), 70.1 (CH2), 69.4 (CH2), 66.5
(CH2), 54.0 (CH), 52.5 (CH), 51.5 (CH3), 50.1 (CH2), 42.1 (CH2),
29.9 (CH2), 28.3 (CH3), 27.6 (CH2), 27.4 (CH2) ppm. MS
(ESI-TOF+) [m/z (%)]: 1281.7 ([MNa]+, 12), 1259.7 ([MH]+, 6),
1039.5 ([MNa − Trt]+, 20), 1017.6 ([MH − Trt]+, 100). HRMS
(ESI) calculated for C66H94N6O18: 1259.6697, found: 1259.6718.
Tr-PEG-Mal-OMe.
A solution of dimethyl 2-(prop-2-yn-1-yl)malonate (48 mg,
0.28 mmol) in a mixture of H2O/MeOH (1 : 1; 46 mL) was
treated with CuSO4 (204 mg, 1.27 mmol) and sodium
L-ascorbate (1.26 g, 6.37 mmol). The mixture was stirred at
room temperature for 15 min, and then a solution of azido-
PEG-amine-Trt (A) (207 mg, 0.25 mmol) in a mixture of H2O/
MeOH (1 : 1, 4 mL) was added. The mixture was stirred at
room temperature for 24 h, and then the solution was treated
with QuadraSil® AP resin to remove any excess Cu. After stir-
ring for 20 min, the resin was filtered and washed with MeOH,
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and then the solvent was removed under reduced pressure.
The resulting residue was purified by flash chromatography
(1–10% MeOH in CH2Cl2) to give 178 mg of Tr-PEG-Mal-OMe
as a light-yellow oil [71%, Rf = 0.54 (10% MeOH/CH2Cl2)].
1H
NMR (CDCl3, 300 MHz, δ): 7.62 (s, 1H), 7.51–7.47 (m, 6H),
7.30–7.16 (m, 10H), 4.51 (t, J = 5.0 Hz, 2H), 3.93 (br, 1H), 3.86
(t, J = 5.0 Hz, 2H), 3.74 (s, 6H), 3.66–3.51 (m, 42H), 3.35 (br, 2
H), 2.36 (t, J = 5.4 Hz, 2H) ppm. 13C NMR (CDCl3, 75 MHz, δ):
168.9 (CO), 145.9 (C), 128.5 (CH), 127.6 (CH), 126.0 (CH), 71.0
(CH2), 70.4 (CH2), 70.2 (CH2), 69.9 (CH2), 69.2 (CH2), 52.5
(CH3), 51.1 (CH), 50.2 (CH2), 42.8 (CH2), 24.8 (CH2) ppm. MS
(ESI-TOF+) [m/z (%)]: 1005.5 ([MNa]+, 9), 983.5 ([MH]+, 8), 763.4
([MNa − Trt]+, 11), 741.4 ([MH − Trt]+, 100). HRMS (ESI) calcu-
lated for C51H75N4O15: 983.5223, found: 983.5257.
Tr-PEG-Glu-Pt-EDA.
A solution of dichloro(ethylenediamine)platinum(II) (31 mg,
0.10 mmol) in H2O (2 mL) was treated with AgNO3 (32 mg,
0.19 mmol). The mixture was protected from light using alu-
minium foil, and it was stirred under Ar at 60 °C for 20 h.
After this time, the mixture was cooled down to room tempera-
ture, filtered through a Celite pad and washed with H2O (3 ×
2 mL). The solvent was concentrated under reduced pressure
until approximately 1 mL.60
Compound Tr-PEG-Glu-OMe (40 mg, 0.032 mmol) was dis-
solved in MeOH (1 mL) before being treated with an aqueous
solution of NaOH (0.5 M, 320 µL, 0.16 mmol), and then the
mixture was stirred at room temperature for 12 h. After
HPLC-MS analysis had confirmed the disappearance of the
starting material, the solvents were concentrated under
reduced pressure and the solid was dried under high vacuum.
The resulting residue was treated with the [Pt(NO3)2EDA]
aqueous solution, which had previously been prepared, and
the solution was stirred at 60 °C for 24 h. Then the reaction
mixture was cooled down to room temperature and concen-
trated under reduced pressure. The resulting residue was dis-
solved in H2O, and the solution was cooled in an ice/water
bath. This formed a precipitate, which was then removed by
centrifugation and decantation. The solution was lyophilized,
giving 45 mg of Tr-PEG-Glu-Pt-EDA as a yellow solid (quantitat-
ive). 1H NMR (D2O, 300 MHz, δ): 7.96 (s, 1H), 7.44–7.18 (m,
6H), 7.15–6.79 (m, 9H), 4.62 (br, 2H), 4.23 (m, 1H), 3.95 (br,
2H), 3.80–3.22 (m, 43H), 3.00–2.55 (m, 6H), 2.52–1.87 (m, 6H),
1.38 (s, 9H) ppm. MS (ESI-TOF+) [m/z (%)]: 1190.5 ([MNa −
Trt]+, 3), 1168.5 ([MH − Trt]+, 100), 935.5 ([MNa − Trt − Pt-
EDA]+, 6), 913.5 ([MH − Trt − Pt-EDA]+, 584.2 ([MH − Trt]2+, 1).
HRMS (ESI) calculated for C41H80N8O18Pt: 1167.5236, found:
1167.5256.
Tr-PEG-Glu-Pt-DACH.
This compound was prepared following the same procedure
described above for Tr-PEG-Glu-Pt-EDA, but [Pt(Cl2)(1R,2R)-
DACH] (36 mg, 0.10 mmol) and compound Tr-PEG-Glu-OMe
(30 mg, 0.024 mmol) were used to give 35 mg of Tr-PEG-Glu-
Pt-DACH as a yellow solid (quantitative). 1H NMR (D2O,
300 MHz, δ): 7.97 (s, 1H), 7.40–7.18 (m, 6H), 7.11–6.81 (m,
9H), 4.65 (m, 2H), 4.24 (m, 1H), 3.98 (br, 2H), 3.79–3.12 (m,
43H), 2.60–1.85 (m, 10H) 1.83–1.06 (m, 17H) ppm. MS
(ESI-TOF+) [m/z (%)]: 1484.6 ([MNa]+, 1), 1462.7 ([MH]+, 1),
1242.5 ([MNa − Trt]+, 7), 1220.6 ([MH − Trt]+, 100), 1177.6 (2),
935.5 ([MNa − Trt − Pt- DACH]+, 8), 913.5 ([MH − Trt − Pt-
DACH]+, 13). HRMS (ESI) calculated for C64H99N8O18Pt:
1462.6724, found: 1462.6692.
Tr-PEG-Mal-Pt-EDA.
This compound was prepared following the same procedure
described above for Tr-PEG-Glu-Pt-EDA, but dichloro(ethylene-
diamine)platinum(II) (29 mg, 0.09 mmol) and compound Tr-
PEG-Mal-Me (30 mg, 0.03 mmol) were used to give 36 mg of
Tr-PEG-Mal-Pt-EDA as a dark-yellow solid (quantitative). 1H
NMR (D2O, 300 MHz, δ): 8.06 (s, 1H), 7.45–7.15 (m, 6H),
7.08–6.76 (m, 9H), 4.66 (br, 2H), 3.99 (d, 2H, J = 16.3 Hz),
3.80–3.13 (m, 45H), 3.01–2.44 (m, 6H), 2.22 (m, 2H) ppm. MS
(ESI-TOF+) [m/z (%)]: 967.4 ([MH − Trt]+, 5), 922.4 ([MH − Trt
− CO2]+, 100), 713.4 ([MH − Trt − Pt-EDA]+, 18), 691.4 ([MNa −
Trt − Pt-EDA − CO2]+, 23), 669.4 ([MH − Trt − Pt-EDA − CO2]+,
62). HRMS (ESI) calculated for C32H64N6O15Pt: 967.4077,
found: 967.4063.
Tr-PEG-Mal-Pt-DACH.
This compound was prepared using the same procedure
described above for Tr-PEG-Glu-Pt-EDA, but [Pt(Cl2)(1R,2R)-
DACH] (34 mg, 0.09 mmol) and compound Tr-PEG-Mal-Me
(30 mg, 0.030 mmol) were used to give 35 mg of the mentioned
compound as a dark yellow solid (quantitative). 1H NMR (D2O,
300 MHz, δ): 8.03 (s, 1H), 7.61–7.16 (m, 6H), 7.12–6.72 (m,
9H), 4.67 (br, 2H), 4.01 (br, 2H), 3.83–3.15 (m, 43H), 2.84–1.92
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(m, 6H), 1.80–1.06 (m, 8H) ppm. MS (ESI-TOF+) [m/z (%)]:
1284.5 ([MNa]+, 4), 1262.6 ([MH]+, 37), 1042.4 ([MNa − Trt]+,
18), 1020.5 ([MH − Trt]+, 79), 976.5 ([MH − Trt − CO2]+, 100),
713.4 ([MH − Trt − Pt-DACH]+, 15), 669.4 ([MH − Trt − Pt-
DACH − CO2]+, 21). HRMS (ESI) calculated for C55H83N6O15Pt:
1262.5563, found: 1262.5569.
Synthesis of MNP-Pt conjugates
MNPs with an average size of 10 nm were prepared by means
of a thermal decomposition approach that has already been
reported. Oleic acid capped MNPs were transferred into water
by a polymer coating procedure that was developed by us.
Then, the surface of the nanoparticles was functionalized with
monoamino-PEG by linking the amino moieties of PEG to the
outstretched carboxy groups of the polymer via EDC chemistry.
This step was introduced to enable the nanoparticles to dis-
solve in DMSO. In detail, 500 molecules of PEG per nano-
particle and 30 000 molecules of EDC per nanoparticle were
used, respectively, starting from a nanoparticle concentration
equal to 1 µM. The reaction occurred in pH 7.4 PBS and, after
3 h stirring at rt, the PEG-functionalized NPs were washed on
centrifuge filters at least 5 times.
Prior to conjugation to the nanoparticles, the trityl-protect-
ing group was removed from the Pt complexes through the use
of a strongly acidic cation exchange resin. In details, the Pt
complexes were dissolved in methanol (1 mg mL−1), and then
the mixture was kept for 18 h in the resin. The resulting
mixture was passed through a column, and the collected solu-
tion was left to dry completely. Finally, the complex was dis-
solved in DMSO immediately before the coupling reaction. A
recent study demonstrated that the use of DMSO may result in
ligand displacement in and changes to the structure of the
complexes, thus inhibiting their anticancer ability.74 Thus,
DMSO was used only for the conjugation step.
The Pt complexes were bound to the nanoparticle surface
as per the following procedure: the nanoparticle solutions in a
PBS/DMSO mixture (1 : 1, 0.5 µM, 200 µL) were treated with an
aqueous solution of EDC (25 mM, 100 µL) for 30 minutes.
Then, the Pt-complex in DMSO (1 mg mL−1, 50 µL) was added,
and the solution was left under stirring for 2 h. Finally, the
MNP-Pt conjugates were thoroughly washed on centrifuge
filters before being dissolved in PBS. The resulting nano-
particles were stored in a fridge. In order to modulate the
number of Pt molecules that were linked to each nanoparticle,
the amount of EDC and Pt-complexes was respectively
adjusted.
Structural and morphological characterization of MNP-Pt
conjugates
Low-magnification TEM images were recorded on a JEOL
Jem1011 microscope operating at an accelerating voltage of
100 kV. Electrophoretic characterization was carried out by
running the nanoparticles through 2% agarose gel immersed
in TBE buffer (pH 8.0) for 1 h at 100 V. DLS and zeta potential
measurements were performed on a Zetasizer Nano ZS90
(Malvern, USA) equipped with a 4.0 mW He–Ne laser operating
at 633 nm and with an avalanche photodiode detector. DLS
measurements were performed in PBS (pH 7.4, with 137 mM
NaCl, 10 mM phosphate, 2.7 mM KCl). FT-IR spectra were
recorded in transmittance mode on a Jasco 6300 spectrometer
(Jasco Corp., Tokyo, Japan) between 4000 and 400 cm−1 with
40 scans and a resolution of 4 cm−1 and analyzed with the
Spectra Manager software (Jasco). Samples were dissolved in
methanol and 50 µL of each solution was poured on the ATR
crystal surface. The spectrum of each sample was acquired
against a background obtained with the crystal without any
sample. All analyses were carried out at room temperature.
The amount of Pt molecules that were linked to each nano-
particle was estimated via elemental analysis using an
Inductively Coupled Plasma Atomic Emission Spectrometer
(ICP-AES) Varian 720-ES. The calibration curves for both Fe
and Pt were prepared, and the relative amount of metal per
sample was estimated upon acidic digestion in HNO3/HCl (1/3)
solution.
Cellular studies
Two human adenocarcinoma cell lineages were used in this
study: ovarian (IGROV-1, a gift from Dr Silvana Canevari,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano,
Italy) and breast (MDA-MB-231, American Type Culture
Collection) cancer cell lines. The cells were grown at 37 °C and
5% CO2 in RPMI-1640 medium supplemented with
L-glutamine, penicillin, streptomycin, and 10% heat-inacti-
vated fetal bovine serum.
MTT viability assay, caspase-3 assay and live/dead assay
To assess the cytotoxic effect of the free Pt complexes and the
MNP-Pt conjugates, three different types of assays were per-
formed: MTT assays, caspase-3 assays, and live/dead assays.
The MTT and caspase-3 assays are both enzymatic tests that
detect the formation of a colorimetric product (MTT) or a fluo-
rescent product (caspase-3) upon the enzymatic cleavage of
specific substrates.
For the MTT assay, the cells (5 × 104 cells) suspended in the
medium (1 mL) were seeded in each well of a 12 well-plate.
After 24 h incubation at 37 °C, a fresh medium containing
either MNP-Pt conjugates, MNP-PEG or free Pt complexes at Pt
concentrations from 0 to 20 µM was added. The cells were kept
under incubation with either free or bound drugs for 24 h.
Next, the medium was removed, and the cells were washed
twice with a phosphate buffer (pH 7.4). 1 mL of serum-free
medium containing 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (1 mg mL−1) was then added into
each well. After 3 h of incubation at 37 °C, the dark insoluble
formazan obtained was dissolved in DMSO (2 mL). The absor-
bance signal at 570 nm was correlated to the percentage of
vital cells by comparing data from treated cells to those of the
control cells. Finally, the IC50 values were determined by plot-
ting the viability percentage against the concentration of the
administered drugs.
In the case of the caspase-3 assay, the cells (5 × 104 in 1 mL
of medium) were seeded in each well of a 12 well-plate. After
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24 h incubation at 37 °C, a fresh medium containing either
MNP-Pt conjugates, MNP-PEG or free Pt complexes at Pt con-
centrations equal to 2 µM was added. In the case of MNP-PEG,
the concentration of nanoparticles that corresponded to the
highest amount of MNP-Pt conjugates was used (0.24 µM).
Two time points (24 and 48 h) were set. Then the fluorometric
caspase-3 Apoptosis Detection Kit from Santa Cruz was used,
and the procedure provided by the company was followed. In
detail, after the lysis and preparation of the cellular samples,
10 µL of the fluorogenic substrate, DEVD-AFC, were added to
the cell lysate and left under incubation for 1 h at 37 °C. Upon
caspase-3 activity, the substrate was cleaved, releasing the fluo-
rescent AFC (7-amino-4-trifluoromethyl coumarin). The mole-
cule was detected by spectrofluorimetry (Cary Eclipse
Fluorimeter) at an excitation wavelength of 400 nm, and the
emission peaked at 505 nm. The caspase-3 activity and thus
the apoptotic status of the treated cells were compared with
that of the control cells.
The live/dead assay (purchased from Invitrogen) was per-
formed on 6 well-plates in which glass coverslips were placed
and then 1 × 105 MDA-MB-231 cells were seeded. After 24 h of
incubation at 37 °C, a fresh medium containing MNP or Pt
complexes (at the same concentration as that reported for the
caspase assay) was added to each well. After 24 h, the cells
were washed with PBS prior to proceeding with the assay proto-
col. In detail, calcein AM (2 µM) and EthD-1 (4 µM) were
added directly to the cells and after 40 minutes of incubation
at room temperature, the solution was removed and fresh PBS
was added. Soon after, the cells were analysed under a confocal
microscope (TCS-SP5, Leica, Mannheim, Germany) using exci-
tation wavelengths of 488 and 543 nm for calcein AM and
EthD-1, respectively. The fluorescence windows were collected
separately, at 530 nm for calcein and at 645 nm for EthD-1. A
quantitative analysis of the pixel intensities for each fluo-
rescent channel was carried out using Leica Application Suite
AF 2.6.3 software (Leica, Mannheim, Germany). The fluo-
rescence intensity within a defined region of interest (ROI) was
normalized with respect to the background signal of the
scanned area.
Quantification of the cellular and nuclear uptake of Pt
The cells (2 × 105 cells) were seeded in each well of a 6 well-
plate (in 2 mL of culture medium). After 24 h, the medium was
replaced with 2 mL of a fresh medium containing either
MNP-PEG-Glu-Pt-EDA or PEG-Glu-Pt-EDA or cisplatin at a sub-
lethal Pt concentration equal to 0.25 µM, corresponding
approximately to a nanoparticle concentration of 5 nM. After
24 h, they were processed for elemental analysis. Next, the
cells were washed three times with PBS and trypsinized. The
cell suspension was then centrifuged, the supernatant was
removed, and a concentrated solution of HCl/HNO3 (3/1, 1 mL)
was added to digest the cells. The intracellular Pt concen-
tration was measured by means of elemental analysis using an
Inductively Coupled Plasma Atomic Emission Spectrometer
(ICP-AES).
To estimate the nuclear uptake of Pt, once the cells were
incubated with either MNP-PEG-Glu-Pt-EDA or PEG-Glu-Pt-
EDA, they were trypsinized, resuspended in TE buffer (10 mM
Tris base, pH 7.6, 0.5 mM EDTA, pH 8.0) with 1% SDS and
then incubated with proteinase K 20 mg mL−1 overnight at
55 °C. Then, the standard protocol for DNA extraction was
used. Finally, a concentrated solution of HCl/HNO3 (3/1, 1 mL)
was added to the DNA prior to run the ICP-AES measurements.
Ultrastructural analysis of cells and tissues
The cells (1 × 106 cells) suspended in 5 mL of medium were
seeded in a culture dish. After 24 h of incubation at 37 °C, the
medium was replaced with a fresh medium containing either
MNP-PEG-Glu-Pt-EDA or MNP-PEG at a sub-lethal concen-
tration of Pt equal to 0.25 µM, corresponding approximately to
a nanoparticle concentration of 30 nM. The cells were then
incubated at 37 °C for 1 h or 24 h. Then, they were washed
with PBS and fixed with glutaraldehyde (2.5%) in cacodylate
buffer (0.1 M) at 4 °C for 30 min. The fixed specimens were
washed three times with the same buffer, and 1% osmium
tetroxide in a cacodylate buffer was added for 1 h. Next, the
cells were washed again and dehydrated with 25%, 50%, 75%
and 100% acetone. Two steps of infiltration in a mixture of
resin/acetone (1/1 and 2/1 ratios) were performed, and then
the specimens were embedded in 100% resin at 60 °C for 48 h.
Ultrathin sections (100 nm thick) were cut on an
Ultramicrotome, then stained with lead citrate and observed
under an electron microscope.
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